Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS Keros Therapeutics (Nasdaq: KROS) entered an agreement on March 9, 2026, with Massachusetts General Hospital to design a Phase 2 clinical trial evaluating rinvatercept in ALS patients under the Healey ALS MyMatch program.The collaboration will use biomarker-driven, personalized trial methods to match ALS subgroups to experimental therapies and to identify optimal populations for later-stage trials.

#KROS Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

www.stocktitan.net/news/KROS/keros-therapeu...

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to

#KROS Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

www.stocktitan.net/news/KROS/keros-therapeu...

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to

#KROS Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/KROS/keros-therapeu...

Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar Bobby Kros, cofounder and head brewer at Kros Strain in La Vista, Nebraska, explains how they gradually shaped Fairy Nectar into an award-winning flagship—and also how they build the double-dry-hopped version differently.

Ask the Pros: How #Kros Strain Dialed in Its Flagship #Hazy #IPA, #FairyNectar | CraftBeerBrewing zurl.co/DD3uA

Artun Talay yazdı:

Krosta niye başarılı olamadık

www.24saatgazetesi.com/krosta-niye-...

#Atletizm #Kros #KrosKoşusu #Balkan #Avrupa

Trade Alerts, Tuesday January 13, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Jan 13th - #XBIT #WLDN #SRTS #PPBT #MITK #KROS #ICHR #FBRX #ELE #DOGZ #CMTL #BBSI #ADAM #TDF #PSBD #MVO #YI #LEG #EVC #BW - More: crystalequityresearch.com/trade-alerts... - #smallcap

aéPiot as a Strategic Asset: A Comprehensive Valuation Analysis. Understanding the True Value of Organic Growth at Scale. aéPiot as a Strategic Asset: A Comprehensive Valuation Analysis Understanding the True Value of Organic Growth at Scale Analysis Date: ...

better-experience.blogspot.com/2026/01/aepi...

#EUSKAL #HERRIKO #ZIKLO #KROS #TXAPELKETA
aepiot.com/advanced-sea...
#VERSTEHEN
aepiot.com/advanced-sea...
#GESTA #KANTAK
multi-search-tag-explorer.headlines-world.com/advanced-sea...
aepiot.com

Lambert & Albert ontmoeten Laura Verdonschot en Rob Peeters, samen met De Ceuster-Bonache-duo, Bram & Niels herinneren aan het recente crossweekend. Nieuws coupé over Niels! #KROS https://fefd.link/iy6hs

Keros Therapeutics Announces Final Results of Tender Offer Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75

#KROS Keros Therapeutics Announces Final Results of Tender Offer

www.stocktitan.net/news/KROS/keros-therapeu...

Keros Therapeutics Announces Preliminary Results of Tender Offer Keros Therapeutics (Nasdaq: KROS) announced preliminary results of a cash tender offer that expired on November 18, 2025 to repurchase up to 10,950,165 shares at $17.75 per share for an aggregate purchase price of approximately $194.4 million. The tender concludes the company’s $375 million capital return program.Approximately 16,659,732 shares were validly tendered (plus 1,186,829 via guaranteed delivery). Keros expects to accept 10,950,165 shares on a pro rata basis, representing about 35.91% of outstanding common stock as of November 18, 2025. Final counts are subject to Depositary confirmation.

#KROS Keros Therapeutics Announces Preliminary Results of Tender Offer

www.stocktitan.net/news/KROS/keros-therapeu...

Leading Indicators, Thursday November 13, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Thu Nov 13th - #CREX #KROS #ZBIO #SHIP #ROOT #PLUS #NAUT #MESA #GECC #CCII #AMAL #NCDL #MFA #HGTY #FPH #EB - More: crystalequityresearch.com/leading-indi... - #smallcap

Current portfolio by size (excluding various <1% positions)

Keros Therapeutics #KROS
Karelia Tobacco Company #KARE.AT
Goodheart-Willcox #GWOX
Gravity #GRVY
Playway S.A. #PLW.WA
Windrock Land Company #WRLC
OTC Markets Group #OTCM
Constellation Software #CSU.TO
[Undisclosed] arb

Keros Therapeutics Reports Third Quarter 2025 Financial Results Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to

#KROS Keros Therapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/KROS/keros-therapeu...

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares Keros Therapeutics (Nasdaq: KROS) commenced a cash tender offer on Oct 20, 2025 to repurchase up to $194.4 million of its common stock at $17.75 per share, part of a previously announced $375 million capital return program. The company expects to fund the tender offer from existing cash and cash equivalents.The offer is scheduled to expire at 5:00 p.m. ET on Nov 18, 2025, unless extended or terminated. The company and its board made no recommendation to shareholders; full terms are filed with the SEC.

#KROS Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

www.stocktitan.net/news/KROS/keros-therapeu...

Trade Alerts, Wednesday October 15, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Wed Oct 15th - #EXPW #KROS #YDKG #WPRT #SDA #PXLW #LNKB #LGO #KARO #EYPT #CBAT #BMR - More: crystalequityresearch.com/trade-alerts... - #smallcap

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital Keros Therapeutics (Nasdaq: KROS) announced agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax at $17.75 per share, for an aggregate purchase price of approximately $181 million, expected to close on October 15, 2025.As part of a previously announced $375 million capital return program, Keros intends to commence a tender offer by the end of October 2025 to repurchase up to $194 million of additional shares at $17.75 per share, funded from existing cash and cash equivalents.The company also plans to distribute 25% of any net cash proceeds received on or before December 31, 2028 from its global license agreement with Takeda to stockholders. Two directors, Ran Nussbaum and Tomer Kariv, resigned effective immediately.

#KROS Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

www.stocktitan.net/news/KROS/keros-therapeu...

FDA Grants Special Status to New Duchenne Muscular Dystrophy Drug: Keros' KER-065 Gets Orphan Designation Keros' KER-065 receives FDA Orphan Drug designation for Duchenne muscular dystrophy treatment. Benefits include tax credits, fee waivers, and 7-year market exclusivity. Phase 2 trial upcoming.

#KROS Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

www.stocktitan.net/news/KROS/keros-announce...

Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches Strategic realignment positions Keros to accelerate KER-065 development for Duchenne muscular dystrophy. Leadership changes support focused approach. Learn key milestones.

#KROS Keros to Exclusively Prioritize the Clinical Advancement of KER-065

www.stocktitan.net/news/KROS/keros-to-exclu...

Keros Therapeutics Reports Second Quarter 2025 Financial Results Keros Therapeutics (NASDAQ: KROS) reported its Q2 2025 financial results, marking significant developments following a comprehensive strategic review. The company posted a net loss of $30.7 million, an improvement from the $45.3 million loss in Q2 2024. Key financial metrics include R&D expenses of $43.5 million and cash position of $690.2 million.The company plans to return $375 million to stockholders while maintaining sufficient capital to fund operations into first half of 2028. Keros is advancing its pipeline, particularly KER-065, with plans to initiate a Phase 2 trial for Duchenne muscular dystrophy in Q1 2026. The company's improved financial position was supported by revenue from its license agreement with Takeda Pharmaceuticals.

#KROS Keros Therapeutics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/KROS/keros-therapeu...

Keros Launches Pivotal Phase 3 Trial for Blood Disorder Drug, Secures $10M from Takeda Partnership First patient dosed in Phase 3 RENEW trial for MDS treatment elritercept. Part of $1.1B potential deal with Takeda. See full milestone details.

#KROS Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

www.stocktitan.net/news/KROS/keros-therapeu...

Rush City Regional airport (United State) aviation weather and informations KROS Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Rush City Regional airport (United State)

Aviation weather for Rush City Regional airport (USA) is “KROS 211555Z AUTO 20011G18KT 10SM CLR 29/22 A2950 RMK AO2” : See what it means on https://www.bigorre.org/aero/meteo/kros/en #rushcity #usa #rushcityregionalairport #kros #metar #aviation #aviationweather #avgeek #airport vl

Rush City Regional airport (United State) aviation weather and informations KROS Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Rush City Regional airport (United State)

Aviation weather for Rush City Regional airport (USA) is “KROS 211535Z AUTO 20012G18KT 10SM CLR 29/22 A2949 RMK AO2 LTG DSNT S” : See what it means on https://www.bigorre.org/aero/meteo/kros/en #rushcity #usa #rushcityregionalairport #kros #metar #aviation #aviationweather #avgeek #airport vl

Rush City Regional airport (United State) aviation weather and informations KROS Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Rush City Regional airport (United State)

Aviation weather for Rush City Regional airport (USA) is “KROS 211455Z AUTO 19012G16KT 10SM CLR 28/23 A2949 RMK AO2 LTG DSNT SE” : See what it means on https://www.bigorre.org/aero/meteo/kros/en #rushcity #usa #rushcityregionalairport #kros #metar #aviation #aviationweather #avgeek #airport vl

JUST IN: ( NASDAQ: #KROS ) ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal ADAR1 Capital Management, Keros Therapeutics' (KROS) largest stockholder, criticizes the company's 2025 Annual Meeting results and capital return strategy. Directors Mary Ann Gray and Alpna Seth received significant opposition, with only 34% and 37% of shares voting for their election respectively. While ADAR1 acknowledges positive steps like discontinuing cibotercept development and reducing headcount, they argue these actions are insufficient. The activist investor demands Keros return $475M to shareholders via special dividend by Q3 2025, implement a contingent value right for Takeda partnership proceeds, and reduce costs more aggressively. ADAR1 threatens to nominate new directors at the 2026 Annual Meeting if the board maintains its current strategy.

#KROS ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

www.stocktitan.net/news/KROS/adar1-issues-s...

Keros Announces Return of $375 Million in Excess Capital to Stockholders Keros Therapeutics (NASDAQ: KROS) has concluded its strategic alternatives review and announced plans to return $375 million in excess capital to stockholders. The company's Board of Directors unanimously approved this decision while maintaining focus on developing KER-065, their lead product candidate for neuromuscular diseases, particularly Duchenne muscular dystrophy. The strategic review process, led by the Board with assistance from outside advisors, evaluated various options including company sale, business combinations, pipeline investment, and capital return. The specific terms and structure of the capital return will be announced at a later date. Lead Independent Director Jean-Jacques Bienaimé emphasized that this decision reflects careful consideration of capital requirements, stockholder feedback, and confidence in Keros's potential to deliver meaningful therapeutic benefits to patients.

#KROS Keros Announces Return of $375 Million in Excess Capital to Stockholders

www.stocktitan.net/news/KROS/keros-announce...

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event Keros CEO presents latest developments in TGF-ß protein therapeutics at Goldman Sachs healthcare conference. Watch live presentation June 9. Get insights.

#KROS Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

www.stocktitan.net/news/KROS/keros-therapeu...

Major Setback: Keros Therapeutics Axes 45% of Staff as Key PAH Drug Trial Fails Safety Tests Following safety concerns in TROPOS trial, Keros halts PAH drug development and announces major restructuring. See details of $17M cost reduction plan and strategic review.

#KROS Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

www.stocktitan.net/news/KROS/keros-therapeu...

Top Proxy Advisor ISS Backs Major Investor's Push Against Keros Directors Over Strategic Review Delay Leading proxy advisor ISS supports ADAR1's opposition to two Keros board members amid strategic review controversy. See why 13.3% shareholder demands immediate action

#KROS ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

www.stocktitan.net/news/KROS/adar1-announce...

Original post on mastodon.social

Aviation weather for Rush City Regional airport (USA) is “KROS 200535Z AUTO 06008KT 7SM RA SCT048 BKN055 OVC065 05/03 A2995 RMK AO2 P0005” : See what it means on https://www.bigorre.org/aero/meteo/kros/en #rushcity #usa #rushcityregionalairport #kros #metar #aviation #aviationweather #avgeek […]